CliffBio
small molecule

JIDEYTRO

ZIDESAMTINIB

Loss of exclusivitySeptember 2042latest FDA-listed patent expiry
CompanyNUVALENT INC

Drug detail

Brand nameJIDEYTRO
Active ingredientZIDESAMTINIB
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2026
Marketing statusRX

Listed patents

PatentExpiresType
12630560September 2042use U-4579
12043626September 2042substance, product
12054498May 2041use U-4579
11542278May 2041substance, product

Regulatory exclusivity

CodeExpires
NCEJuly 2031

More from NUVALENT INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.